Bioventus Inc. financial data

Symbol
BVS on Nasdaq
Location
Durham, NC
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 158% % 14%
Quick Ratio 54% % 22%
Debt-to-equity 297% % -20%
Return On Equity 11% %
Return On Assets 3.3% %
Operating Margin 9.5% %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $264,400,000 USD 50%
Weighted Average Number of Shares Outstanding, Basic 66,622,631 shares 3.2%
Weighted Average Number of Shares Outstanding, Diluted 68,914,895 shares 6.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $568,087,000 USD -0.91%
Research and Development Expense $12,113,000 USD -13%
Operating Income (Loss) $53,975,000 USD 153%
Nonoperating Income (Expense) $28,266,000 USD 24%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $25,709,000 USD
Income Tax Expense (Benefit) $1,565,000 USD 70%
Net Income (Loss) Attributable to Parent $22,732,000 USD
Earnings Per Share, Basic 0.34 USD/shares
Earnings Per Share, Diluted 0.33 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $51,238,000 USD 23%
Accounts Receivable, after Allowance for Credit Loss, Current $128,303,000 USD 0.71%
Inventory, Net $82,236,000 USD -11%
Assets, Current $272,842,000 USD -1%
Deferred Income Tax Assets, Net $4,745,000 USD -36%
Operating Lease, Right-of-Use Asset $5,122,000 USD -21%
Intangible Assets, Net (Excluding Goodwill) $368,419,000 USD -9%
Goodwill $7,462,000 USD 0%
Assets $683,559,000 USD -6.1%
Accounts Payable, Current $10,928,000 USD -54%
Accrued Liabilities, Current $130,242,000 USD -4.1%
Contract with Customer, Liability, Current $955,000 USD -43%
Liabilities, Current $160,380,000 USD -24%
Deferred Income Tax Liabilities, Net $433,000 USD -23%
Operating Lease, Liability, Noncurrent $4,456,000 USD -36%
Other Liabilities, Noncurrent $15,348,000 USD -34%
Liabilities $455,112,000 USD -16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,900,000 USD 26%
Retained Earnings (Accumulated Deficit) $334,929,000 USD 6.4%
Stockholders' Equity Attributable to Parent $184,105,000 USD 24%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $228,447,000 USD 23%
Liabilities and Equity $683,559,000 USD -6.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $19,331,000 USD -222%
Net Cash Provided by (Used in) Financing Activities $947,000 USD
Net Cash Provided by (Used in) Investing Activities $826,000 USD 17%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $18,780,000 USD -59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $51,238,000 USD 23%
Deferred Tax Assets, Valuation Allowance $47,579,000 USD -8.3%
Deferred Tax Assets, Gross $53,101,000 USD -6.2%
Operating Lease, Liability $7,759,000 USD -23%
Payments to Acquire Property, Plant, and Equipment $826,000 USD 184%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $23,405,000 USD
Lessee, Operating Lease, Liability, to be Paid $8,218,000 USD -24%
Operating Lease, Liability, Current $3,303,000 USD 6.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,066,000 USD -7.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,582,000 USD 2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.052 pure 2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $459,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,548,000 USD -42%
Deferred Tax Assets, Operating Loss Carryforwards $9,916,000 USD 7.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $920,000 USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year Four $22,000 USD -98%
Operating Lease, Payments $892,000 USD -24%
Additional Paid in Capital $520,851,000 USD 2.5%
Depreciation, Depletion and Amortization $11,865,000 USD 0.68%
Deferred Tax Assets, Net of Valuation Allowance $5,522,000 USD 16%
Share-based Payment Arrangement, Expense $12,193,000 USD -5%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%